CD4 and neoplasm: As seen with ICB-treated heterozygous Map3k7f/wt KPPC tumors, the combination of Takinib and ICB resulted in higher infiltration of total and proliferating CD4+ and CD8+ T cells (Fig. 7P), as well as closer proximity between proliferating CD8+ T and tumor cells (Fig. 7Q).